|Dr. Richard Chin||Co-Founder, CEO & Director||743.6k||N/A||1967|
|Ms. Denise M. Bevers||Co-Founder, Pres, COO, Sec. & Director||590.56k||N/A||1967|
|Ms. Wendy K. Wee||Chief Financial Officer||414.5k||N/A||1953|
|Dr. Hangjun Zhan||Chief Scientific Officer||419.1k||N/A||1960|
|Ms. Katja Buhrer||VP of Corp. Devel. & Investor Relations||N/A||N/A||N/A|
Kindred Biosciences, Inc., a commercial-stage biopharmaceutical company, focusing on developing therapies for pets. Its product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. The company offers Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats. It is also developing Zimeta IV and Zimeta Oral for the control of fever in horses. In addition, the company develops KIND-016, a monoclonal antibody for the treatment of atopic dermatitis in dogs; KIND-014 to treat gastric ulcers in horses; epoCat, a feline recombinant erythropoietin for the management of anemia in cats; KIND-011, a monoclonal antibody that targets sick or septic foals; and KIND-509, an antibody for canine inflammatory bowel disease. Further, it is developing KIND-015 for the management of clinical signs associated with equine metabolic syndrome and anti-tumor necrosis factor in septic foals; KIND-502, an IgE antibody that targets the canine counterpart of the human target for allergic and immune-mediated diseases; KIND-0888, an antibody that targets CD20; and various antibodies that target cytokines involved in atopic dermatitis, as well as interleukin antibodies and canine checkpoint inhibitors. Kindred Biosciences, Inc. was founded in 2012 and is headquartered in Burlingame, California.
Kindred Biosciences, Inc.’s ISS Governance QualityScore as of June 25, 2019 is 9. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 9; Compensation: 9.